SEQ_NO | 1 | Date of announcement | 2023/11/17 | Time of announcement | 17:50:52 |
Subject | Microbio Co., Ltd. receives a R.O.C. patent on the new drug MS-20 (CHEMO YOUNG). | ||||
Date of events | 2023/11/17 | To which item it meets | paragraph 53 | ||
Statement | 1.Date of occurrence of the event:2023/11/17
2.Company name:Microbio Co., LTD. 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):head office 4.Reciprocal shareholding ratios:NA 5.Cause of occurrence: The Company has been informed by the patent agency that the new drug: MS-20 has been granted a Republic of China patent titled “METHOD OF ACTIVATING TUMOR-INFILTRATING LYMPHOCYTES (TILS)」” under patent number I817977. 6.Countermeasures:None 7.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.): (1)The new drug MS-20 has obtained patents from the U.S., the Republic of China, Japan, the People’s Republic of China, the Hong Kong Special Administrative Region, Europe, Korea, Indonesia, India, Canada, Singapore, Malaysia, Brazil, and United Arab Emirates. (2)This patent presents a combination therapy with Chemoyoung (MS-20) and anti-PD1 antibody in colon cancers where the tumor-infiltrating lymphocytes (TILs) were increased and migrated into the cancer cells. This transformed a cold tumor to a hot tumor and improved the effect of immunotherapy, leading to the significant reduction of the tumor volume. |
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.